Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared on X:
“More Than 50 ADCs at ESMO 2026.
How Many Will Actually Change Clinical Practice?
Four questions matter:
- Meaningful OS/PFS benefit?
- Appropriate comparator?
- Acceptable toxicity?
- Better patient selection?
More ADCs do not automatically mean better outcomes.”
Other articles about ADCs on Oncodaily.